683 related articles for article (PubMed ID: 34710849)
21. Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data.
Ates O; Oksuzoglu OB; Aktas BY; Karadag I; Esen S; Karakaya S; Uncu D; Erol C; Gurbuz M; Yalcin B; Aksoy S
J BUON; 2021; 26(4):1398-1404. PubMed ID: 34564997
[TBL] [Abstract][Full Text] [Related]
22. Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience.
Kim JY; Nam SJ; Lee JE; Yu J; Chae BJ; Lee SK; Ryu JM; Ahn JS; Im YH; Kim SW; Park YH
Cancer Res Treat; 2022 Oct; 54(4):1091-1098. PubMed ID: 35008143
[TBL] [Abstract][Full Text] [Related]
23. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
[TBL] [Abstract][Full Text] [Related]
24. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.
Schneeweiss A; Chia S; Hickish T; Harvey V; Eniu A; Waldron-Lynch M; Eng-Wong J; Kirk S; Cortés J
Eur J Cancer; 2018 Jan; 89():27-35. PubMed ID: 29223479
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
Chen S; Liang Y; Feng Z; Wang M
BMC Cancer; 2019 Oct; 19(1):973. PubMed ID: 31638935
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
Lavasani SM; Somlo G; Yost SE; Frankel PH; Ruel C; Cui Y; Murga M; Tang A; Martinez N; Kruper L; Tumyan L; Schmolze D; Yeon C; Yuan Y; Waisman JR; Mortimer J
Cancer; 2023 Mar; 129(5):740-749. PubMed ID: 36517940
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer.
Gupta A; Gogia A; Deo S; Sharma DN; Mathur S; Sagiraju HKR
Cancer Treat Res Commun; 2023; 36():100741. PubMed ID: 37453371
[TBL] [Abstract][Full Text] [Related]
29. Cardiac safety of neoadjuvant chemotherapy with epirubicin and cyclophosphamide followed by docetaxel/pertuzumab/trastuzumab for HER2-positive breast cancer patients.
Douganiotis G; Grigoriadis S; Kontovinis L; Markopoulou E; Pouptsis A; Papazisis K
J BUON; 2021; 26(3):714-719. PubMed ID: 34268925
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
[TBL] [Abstract][Full Text] [Related]
31. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
Choi JH; Jeon CW; Kim YO; Jung S
Medicine (Baltimore); 2020 Nov; 99(46):e23053. PubMed ID: 33181670
[TBL] [Abstract][Full Text] [Related]
32. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.
Conte B; Fabi A; Poggio F; Blondeaux E; Dellepiane C; D'Alonzo A; Buono G; Arpino G; Magri V; Naso G; Presti D; Mura S; Fontana A; Cognetti F; Molinelli C; Pastorino S; Bighin C; Miglietta L; Boccardo F; Lambertini M; Del Mastro L;
Clin Breast Cancer; 2020 Apr; 20(2):e181-e187. PubMed ID: 31735691
[TBL] [Abstract][Full Text] [Related]
33. Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience.
Boér K; Kahán Z; Landherr L; Csőszi T; Máhr K; Ruzsa Á; Horváth Z; Budai B; Rubovszky G
Pathol Oncol Res; 2021; 27():1609785. PubMed ID: 34257621
[No Abstract] [Full Text] [Related]
34. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
González-Santiago S; Saura C; Ciruelos E; Alonso JL; de la Morena P; Santisteban Eslava M; Gallegos Sancho MI; de Luna A; Dalmau E; Servitja S; Ruiz Borrego M; Chacón JI
Breast Cancer Res Treat; 2020 Nov; 184(2):469-479. PubMed ID: 32876911
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
Bonnefoi H; Jacot W; Saghatchian M; Moldovan C; Venat-Bouvet L; Zaman K; Matos E; Petit T; Bodmer A; Quenel-Tueux N; Chakiba C; Vuylsteke P; Jerusalem G; Brain E; Tredan O; Messina CG; Slaets L; Cameron D
Ann Oncol; 2015 Feb; 26(2):325-32. PubMed ID: 25467016
[TBL] [Abstract][Full Text] [Related]
36. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.
Bueno-Muiño C; Echavarría I; López-Tarruella S; Roche-Molina M; Del Monte-Millán M; Massarrah T; Jerez Y; Ayala de la Peña F; García-Sáenz JÁ; Moreno F; Rodríguez-Lescure Á; Malón-Giménez D; Ballesteros García AI; Marín-Aguilera M; Galván P; Brasó-Maristany F; Waks AG; Tolaney SM; Mittendorf EA; Vivancos A; Villagrasa P; Parker JS; Perou CM; Paré L; Villacampa G; Prat A; Martín M
JAMA Oncol; 2023 Jun; 9(6):841-846. PubMed ID: 37103916
[TBL] [Abstract][Full Text] [Related]
37. Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer.
Echavarria I; Granja M; Bueno C; Lopez-Tarruella S; Peinado P; Sotelo M; Jerez Y; Moreno F; Torres G; Lobo M; Marquez-Rodas I; Del Monte-Millan M; Martín M; García-Saenz JA
Breast Cancer Res Treat; 2017 Feb; 162(1):181-189. PubMed ID: 28040858
[TBL] [Abstract][Full Text] [Related]
38. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients.
He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ
Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098
[TBL] [Abstract][Full Text] [Related]
39. Impact of Dose Intensity on Pathologic Complete Response Rate in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP).
Le D; Vargo C; Collins S; Williams N; Palettas M; Berger M
Target Oncol; 2022 Mar; 17(2):167-175. PubMed ID: 35325355
[TBL] [Abstract][Full Text] [Related]
40. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.
Shao Z; Pang D; Yang H; Li W; Wang S; Cui S; Liao N; Wang Y; Wang C; Chang YC; Wang H; Kang SY; Seo JH; Shen K; Laohawiriyakamol S; Jiang Z; Li J; Zhou J; Althaus B; Mao Y; Eng-Wong J
JAMA Oncol; 2020 Mar; 6(3):e193692. PubMed ID: 31647503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]